Clinical-stage developer of small-molecule senolytics that selectively clear pathologic senescent cells driving age-related disease.
Seattle biotech using a non-viral lipid delivery platform to deliver gene-directed payloads that destroy senescent cells.
Join to open the full comparison.
The Briefing, free for life.